Recent Posts:
- Abbexa celebrates commitment to Real Living Wage
- The Journey of Alzheimer's: From Understanding to Hope
- Abbexa Appoints NuLife as a Distributor in India 2023
- The Spread and Control of Avian Influenza
- Do current COVID-19 vaccines protect against brain damage?
- The Emergence of Monkeypox
- A COVID-19 Vaccine using Modified Bacterial DNA
- Abbexa achieves ISO 9001:2015 accreditation
- Investors in People Accreditation Awarded
- American Diabetes Association Alert Day
The Emergence of Monkeypox
Posted on 2022-09-02
Monkeypox was recently declared a public health emergency, having had more than 50,000 cases confirmed worldwide. Monkeypox is an enveloped double-stranded DNA virus, that occurs primarily in tropical rainforest areas of central and West Africa. It has comparable symptoms to that of smallpox, but less severe.
It enters the host through oropharynx, nasopharynx or intradermal routes. Symptoms can include, high fever, headache, lymphadenopathy, systemic blisters and pustules.
The pathogen
There are two distinct genetic clades of the monkeypox virus. This includes the central African (Congo Basin) clade and the west African clade. The Congo Basin clade has historically caused more severe disease and was thought to be more transmissible.
Similarities to Smallpox
The clinical presentation of monkeypox resembles that of smallpox. Smallpox is a related orthopoxvirus infection which was declared eradicated worldwide in 1980. Monkeypox is less contagious than smallpox, with less severe illness.
Vaccines used during the smallpox eradication programme also provided protection against monkeypox.
More recently, newer vaccines have been developed. One vaccine has been approved for the prevention of monkeypox, as well as an antiviral agent which has been licensed for treatment.
Signs and Symptoms
The incubation period (from infection to onset of symptoms) of monkeypox is usually 6 to 13 days but can range from 5 to 21 days.
The infection can be divided into two periods:
The invasion period (0–5 days) consists of fever, intense headaches, swelling of the lymph nodes, back pain, muscle aches, and a lack of energy. Swelling of the lymph nodes is a distinctive feature of monkeypox.
Skin eruption usually begins within 1–3 days of a fever. This is a rash concentrated to the face and extremities. Most commonly, rashes are seen on the face, palms of hands and soles of the feet. Lesions may also appear, and can vary from a few, to thousands.
Abbexa is proud to offer an extensive range of products to support research into Monkeypox.
Abbexa's Monkeypox Product Range:
Paired Monkeypox Antibodies and Proteins | |
Monkeypox Virus A29L(MPXV A29L) Antibody | abx376566 |
Monkeypox Virus A29L (MPXV A29L) Protein | abx620109 |
Monkeypox Virus Cell Surface-Binding Protein (MPXV E8L) Antibody | abx376565 |
Monkeypox Virus Cell Surface-Binding Protein (MPXV E8L) Protein | abx620107 |
Monkeypox Virus M1R (MPXV M1R) Antibody | abx376563 |
Monkeypox Virus M1R (MPXV M1R) Antibody | abx376564 |
Monkeypox Virus M1R (MPXV M1R) Protein | abx620108 |
Monkeypox Kits | |
Human Monkeypox Virus IgG (MPXV IgG) ELISA Kit | abx392298 |
Human Monkeypox Virus IgM (MPXV IgM) ELISA Kit | abx392299 |
Human Monkeypox Virus IgG/IgM (MPXV IgG/IgM) Rapid Test Kit | abx092183 |
Monkeypox Virus (MPXV) RT-PCR Kit | abx471001 |
View the full list of our extensive range of products for research into Monkeypox here
Sources/Further reading:
Discover further details on Monkeypox from the World Health Organisation here
For more information from the CDC, navigate here
For more information from the NHS, navigate here